Fresenius Medical Care AG (FMCQF)
| Market Cap | 12.79B -9.2% |
| Revenue (ttm) | 22.19B -0.5% |
| Net Income | 1.07B +42.9% |
| EPS | 3.82 +50.0% |
| Shares Out | n/a |
| PE Ratio | 11.93 |
| Forward PE | 10.88 |
| Dividend | 1.73 (3.36%) |
| Ex-Dividend Date | May 22, 2026 |
| Volume | 159 |
| Open | 51.44 |
| Previous Close | 49.82 |
| Day's Range | 51.44 - 51.44 |
| 52-Week Range | 42.00 - 56.24 |
| Beta | 0.82 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Fresenius Medical Care AG
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospital... [Read more]
Financial Performance
In 2025, Fresenius Medical Care AG's revenue was 19.63 billion, an increase of 1.51% compared to the previous year's 19.34 billion. Earnings were 978.37 million, an increase of 81.88%.
Financial numbers in EUR Financial StatementsNews
Fresenius Medical price target raised to $25.80 from $25.50 at Bernstein
Bernstein analyst Susannah Ludwig raised the firm’s price target on Fresenius Medical (FMS) to $25.80 from $25.50 and keeps a Market Perform rating on the shares. The firm notes the…
Fresenius Medical price target lowered to EUR 32.30 from EUR 37.40 at JPMorgan
JPMorgan analyst David Adlington lowered the firm’s price target on Fresenius Medical (FMS) to EUR 32.30 from EUR 37.40 and keeps an Overweight rating on the shares. Published first on…
Fresenius Medical price target lowered to EUR 31 from EUR 32 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Fresenius Medical (FMS) to EUR 31 from EUR 32 and keeps an Underweight rating on the shares.
Fresenius Medical price target lowered to $25 from $26 at Truist
Truist lowered the firm’s price target on Fresenius Medical (FMS) to $25 from $26 and keeps a Hold rating on the shares.
Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights
Fresenius Medical Care AG & Co. KGaA NYSE: FMS reported second-quarter 2026 organic revenue growth of 5% and a 23% increase in operating income at constant currency, while confirming its full-year out...
Fresenius Medical Care Shares Drop After U.S. Treatment Volumes Fall Further
Shares fell, wiping out most of their gains since the start of the year, after the German dialysis specialist reported another decline in U.S. treatment volumes in the second quarter.
Fresenius Medical Care AG Earnings Call Transcript: Q2 2026
Operating income grew 23% year-over-year with margin expansion and strong cash flow, despite U.S. treatment volume headwinds and regulatory challenges in China. A EUR 1 billion share buyback was completed and a second program launched, while guidance for 2026 was confirmed.
Fresenius Medical Care AG Earnings release: Q2 2026
Fresenius Medical Care AG released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Fresenius Medical Care AG Slides: Q2 2026
Fresenius Medical Care AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Fresenius Medical Care AG Quarterly report: Q2 2026
Fresenius Medical Care AG has published its Q2 2026 quarterly earnings report on August 4, 2026.
Dialysis firm FMC's shares slide despite earnings beat as US volumes disappoint again
Fresenius Medical Care shares fell in early trade on Tuesday, as investors looked past a second-quarter profit beat to focus on a fresh disappointment in U.S. patient volumes and the management's de...
Fresenius Medical Care beats quarterly profit estimates, sticks to 2026 outlook
Fresenius Medical Care on Monday reported second-quarter operating income well ahead of market expectations and reaffirmed its full-year outlook, as its cost-cutting programme and favourable U.S. re...
Fresenius Medical downgraded to Underperform from Neutral at BNP Paribas
BNP Paribas downgraded Fresenius Medical (FMS) to Underperform from Neutral with a $19.90 price target The firm expects U.S. dialysis volumes to “stay lower for longer.”
Fresenius Medical price target raised to EUR 41 from EUR 40 at Citi
Citi raised the firm’s price target on Fresenius Medical (FMS) to EUR 41 from EUR 40 and keeps a Neutral rating on the shares.
Fresenius Medical initiated with a Market Perform at Bernstein
Bernstein initiated coverage of Fresenius Medical (FMS) with a Market Perform rating and EUR 44.65 price target Dialysis, particularly in the U.S. where the company is over-indexed, has been a…
Focus Graphite Announces SEDAR+ Filing of the NI 43-101 Technical Report with the Updated Mineral Resource for the Lac Tetepisca Project
One of the Largest Identified Graphite Deposits Globally with 120.2 Mt Indicated at 10.27% Cg and 24.1 Mt Inferred at 9.88% Cg, Containing 14.7 Mt of In-Situ Graphite Ottawa, Ontario--(Newsfile Corp. ...
Focus Graphite Completes Final Major ESIA Technical Study, Advancing Lac Knife Toward Permitting
Hydrogeological Assessment Concludes Multi-Year Environmental Program and Supports Upcoming ESIA Submission Ottawa, Ontario--(Newsfile Corp. - June 15, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: ...
Fresenius Medical Care launches kinexus worldwide, a unified digital platform to support home dialysis
Global launch of a single, integrated digital platform connecting remote therapy monitoring and operational workflows for home dialysis programs Designed to simplify care processes for healthcare team...
Fresenius Medical launches first tranche of share buyback program
Fresenius Medical (FMS) Care announced the launch of the first tranche of its new share buyback program with a total volume of around EUR 1B. The first tranche, amounting up…
Fresenius Medical Care launches first tranche of its share buyback program of up to EUR 600 million
BAD HOMBURG, Germany, May 28, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the launch o...
Fresenius Medical Care highlights new renal research and innovation at ERA Congress 2026
Hemodiafiltration (HDF) research reinforces Fresenius Medical Care's continued leadership in advancing evidence-based dialysis care and treatment personalization New research focuses on applying real-...
Fresenius Medical announces EUR 1B share buyback program
Fresenius Medical (FMS) Care intends to execute a new share buyback program with a total volume of around EUR 1B. The program shall be executed in tranches over a period…
Fresenius Medical Care announces new share buyback program with a total volume of around EUR 1 billion with phased execution over 12 months
Total volume of the share buyback is around EUR 1 billion over 12 months Share buyback expected to begin in the near future BAD HOMBURG, Germany, May 26, 2026 /PRNewswire/ -- Fresenius Medical Care (F...
Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney care
Shareholders approve proposed dividend of EUR 1.49 per share FME Reignite strategy launched in 2025 successfully drives the next phase of value creation 5008X CAREsystem introduced in U.S. clinics; fu...
Fresenius Medical Care AG Transcript: AGM 2026
The AGM highlighted robust financial growth, a successful transformation program, and the launch of a new five-year strategy. Leadership changes, a dividend increase, and a major U.S. product rollout were announced, with continued focus on innovation and operational excellence.